SCHEMBL7970258

SCHEMBL7970258

CCNC(=O)c1ccc2c(c1F)CN(Cc1ccc(OC)cc1)C2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 2/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC6 Q9UBN7 2/20 0.41
POLB P06746 1/20 0.41
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
MMP1 P03956 1/20 0.39
MMP13 P45452 1/20 0.39
MAPK1 P28482 1/20 0.39
HDAC1 Q13547 2/20 0.39
LMNA P02545 3/20 0.38
CACNA1G O43497 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP1A2 P05177 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7967987 0.90 IDH1 (0.46) IDH1MEN1KMT2AHDAC6POLB
SCHEMBL7983771 0.88 IDH1 (0.48) IDH1MEN1KMT2AHDAC6POLB
SCHEMBL1418449 0.87 IDH1 (0.47) IDH1MEN1KMT2AHDAC6POLB
SCHEMBL7981153 0.87 IDH1 (0.48) IDH1HDAC6POLBCYP2C19MMP1
SCHEMBL7983775 0.81 MEN1 (0.45) IDH1MEN1KMT2AHDAC6POLB
SCHEMBL12810295 0.78 MEN1 (0.39) IDH1MEN1KMT2ACYP2C19HDAC1
SCHEMBL7984504 0.77 CACNA1G (0.50) MEN1KMT2AHDAC6MMP13MAPK1
SCHEMBL1418406 0.75 CACNA1G (0.50) MEN1KMT2AHDAC6MMP13MAPK1
SCHEMBL31159232 0.73 IDH1 (0.52) IDH1MEN1KMT2APOLBLMNA
SCHEMBL30908494 0.70 IDH1 (0.49) IDH1MEN1KMT2AHDAC6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 IDH1 235/4885MEN1 2484/4885KMT2A 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.